Clinical review for general practice

ISSN (Print) 2713-2552
ISSN (Online) 2782-5671
  • Home
  • about
  • archives
  • contacts
left
FULLSCREEN > Archive > 2024 > Incidence and prevalence of pulmonary arterial hypertension associated with systemic lupus erythematosus. A systematic review

Incidence and prevalence of pulmonary arterial hypertension associated with systemic lupus erythematosus. A systematic review

Vadim D. Zakiev , Tamila V. Martynyuk , Yulia V. Kotovskaya

For citation:


  • Abstract
  • About the Author
  • References

Abstract

Relevance. Pulmonary arterial hypertension (PAH) is a rare complication of systemic lupus erythematosus (SLE). Due to the nonspecificity of symptoms and difficulties in diagnosis, the exact incidence and prevalence of PAH associated with SLE is unknown. 
Aim. A systematic review of studies assessing the incidence and prevalence of PAH associated with SLE. 
Material and methods. A systematic search was performed for studies investigating the incidence and prevalence of PAH associated with SLE published from January 1, 2000 to December 31, 2023. The search was carried out in the PubMed/MEDLINE database for English-language publications and in the RSCI database for studies in Russian according to pre-defined inclusion and exclusion criteria.
Results. 53 potential publications were identified, all sources in English. 11 publications remained for further assessment after screening article titles and abstracts. After detailed analysis, 6 articles were excluded because they did not meet the inclusion and exclusion criteria. Totally, 5 studies were included in the systematic review. Three studies assessed prevalence only, one study assessed incidence only, and one study assessed both prevalence and incidence. The prevalence of PAH associated with SLE ranged from 0 to 4.2%, with 3-year and 5-year cumulative incidence rates of 0.53–1.2% and 0.77–1.8%, respectively. 
Conclusion. A systematic review showed a low prevalence and incidence of PAH associated with SLE. 
Key words: pulmonary arterial hypertension, systemic lupus erythematosus, incidence, prevalence, systematic review.

About the Author

Vadim D. Zakiev 1 , Tamila V. Martynyuk 2 , Yulia V. Kotovskaya 1

1 Pirogov Russian National Research Medical University, Moscow, Russia;

2 Pirogov Russian National Research Medical University, Moscow, Russia; Chazov National Medical Research Center for Cardiology, Moscow, Russia

References

1. Kamath SD, Ahmed T, Upadhyay A, Agarwal V. Pulmonary Arterial Hypertension (PAH) as the Initial Manifestation of Systematic Lupus Erythematosus (SLE): A Rare Presentation. Cureus 2023;15(5):e39359. DOI: 10.7759/cureus.39359
2. Humbert M, Kovacs G, Hoeper MM et al; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022;43(38):3618-731. DOI: 10.1093/eurheartj/ehac237. Erratum in: Eur Heart J 2023;44(15):1312.
3. Maron BA. Revised Definition of Pulmonary Hypertension and Approach to Management: A Clinical Primer. J Am Heart Assoc 2023;12(8):e029024. DOI: 10.1161/JAHA.122.029024
4. D'Alto M, Dimopoulos K, Coghlan JG et al. Right Heart Catheterization for the Diagnosis of Pulmonary Hypertension: Controversies and Practical Issues. Heart Fail Clin 2018;14(3):467-77. DOI: 10.1016/j.hfc.2018.03.011
5. Gonzalez-Hermosillo LM, Cueto-Robledo G, Roldan-Valadez E et al. Right Heart Catheterization (RHC): A Comprehensive Review of Provocation Tests and Hepatic Hemodynamics in Patients With Pulmonary Hypertension (PH). Curr Probl Cardiol 2022;47(12):101351. DOI: 10.1016/j.cpcardiol.2022.101351
6. Rosenkranz S, Preston IR. Right heart catheterisation: best practice and pitfalls in pulmonary hypertension. Eur Respir Rev 2015;24(138):642-52. DOI: 10.1183/16000617.0062-2015
7. Topyła-Putowska W, Tomaszewski M, Wysokiński A, Tomaszewski A. Echocardiography in Pulmonary Arterial Hypertension: Comprehensive Evaluation and Technical Considerations. J Clin Med 2021;10(15):3229. DOI: 10.3390/jcm10153229
8. Ferrara F, Zhou X, Gargani L et al. Echocardiography in Pulmonary Arterial Hypertension. Curr Cardiol Rep 2019;21(4):22. DOI: 10.1007/s11886-019-1109-9
9. Amarnani R, Yeoh SA, Denneny EK, Wincup C. Lupus and the Lungs: The Assessment and Management of Pulmonary Manifestations of Systemic Lupus Erythematosus. Front Med (Lausanne) 2021;7:610257. DOI: 10.3389/fmed.2020.610257
10. Tselios K, Urowitz MB. Cardiovascular and Pulmonary Manifestations of Systemic Lupus Erythematosus. Curr Rheumatol Rev 2017;13(3):206-18. DOI: 10.2174/1573397113666170704102444
11. Didden EM, Lee E, Wyckmans J et al. Time to diagnosis of pulmonary hypertension and diagnostic burden:Aretrospective analysis of nationwide US healthcare data. Pulm Circ 2023;13(1):e12188. DOI: 10.1002/pul2.12188
12. Badesch DB, Raskob GE, Elliott CG et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010;137(2):376-87. DOI: 10.1378/chest.09-1140
13. Humbert M, Sitbon O, Chaouat A et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006;173(9):1023-30. DOI: 10.1164/rccm.200510-1668OC Литература / References 80 | КЛИНИЧЕСКИЙ РАЗБОР В ОБЩЕЙ МЕДИЦИНЕ | ТОМ 5 | №2 | 2024 | Clinical review for general practice | VOL. 5 | No. 2 | 2024 |
14. Parperis K, Velidakis N, Khattab E et al. Systemic Lupus Erythematosus and Pulmonary Hypertension. Int J Mol Sci 2023;24(6):5085. DOI: 10.3390/ijms24065085
15. Prabu A, Patel K, Yee CS et al. Prevalence and risk factors for pulmonary arterial hypertension in patients with lupus. Rheumatology (Oxford) 2009;48(12):1506–11. DOI: 10.1093/rheumatology/kep203
16. Ruiz-Irastorza G, Garmendia M, Villar I et al. Pulmonary hypertension in systemic lupus erythematosus: prevalence, predictors and diagnostic strategy. Autoimmun Rev 2013;12(3):410-5. DOI: 10.1016/j.autrev.2012. 07.010
17. Pérez-Peñate GM, Rúa-Figueroa I, Juliá-Serdá G et al. Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: Prevalence and Predictors. J Rheumatol 2016;43(2):323-9. DOI: 10.3899/jrheum.150451
18. Chen HA, Hsu TC, Yang SC et al. Incidence and survival impact of pulmonary arterial hypertension among patients with systemic lupus erythematosus: a nationwide cohort study. Arthritis Res Ther 2019;21(1):82. DOI: 10.1186/s13075-019-1868-0
19. Atsumi T, Tan JY, Chiang AP et al. Prevalence, patient characteristics and treatment patterns among SLE-PAH patients in real-world clinical practice: A retrospective analysis of Medical Data Vision Database in Japan. Mod Rheumatol 2023 Sep 25:road090. DOI: 10.1093/mr/ road090. Epub ahead of print.
20. Rubio-Rivas M, Homs NA, Cuartero D, Corbella X. The prevalence and incidence rate of pulmonary arterial hypertension in systemic sclerosis: Systematic review and meta-analysis. Autoimmun Rev 2021; 20(1):102713. DOI: 10.1016/j.autrev.2020.102713
21. Kim JS, Kim D, Joo YB et al. Factors associated with development and mortality of pulmonary hypertension in systemic lupus erythematosus patients. Lupus 2018;27(11):1769–77. DOI: 10.1177/09612033187 88163
22. Xu SZ, Yan Liang, Li XP et al. Features associated with pulmonary arterial hypertension in Chinese hospitalized systemic lupus erythematosus patients. Clin Rheumatol 2018;37(6):1547–53. DOI: 10.1007/s10067-018-4056-8
23. Li M, Wang Q, Zhao J, et al; CSTAR co-authors. Chinese SLE Treatment and Research group (CSTAR) registry: II. Prevalence and risk factors of pulmonary arterial hypertension in Chinese patients with systemic lupus erythematosus. Lupus 2014;23(10):1085-91. DOI: 10.1177/0961203314527366
24. JohnsonSR,GladmanDD,UrowitzMBet al.Pulmonaryhypertensioninsystemic lupus. Lupus 2004;13(7):506-9. DOI: 10.1191/0961203303lu1051oa
25. Mathai SC, Hemnes AR, Manaker S et al. Identifying Patients with Pulmonary Arterial Hypertension Using Administrative Claims Algorithms. Ann Am Thorac Soc 2019;16(7):797-806. DOI: 10.1513/AnnalsATS.201810-672CME
26. Chang WT, Weng SF, Hsu CH et al. Prognostic Factors in Patients With Pulmonary Hypertension-A Nationwide Cohort Study. J Am Heart Assoc 2016;5(9):e003579. DOI: 10.1161/JAHA.116.003579
27. Чельдиева Ф.А., Решетняк Т.М., Раденска-Лоповок С.Г. и др. Антифосфолипидный синдром и системная красная волчанка: какое заболевание является причиной повреждения органов? Научнопрактическая ревматология. 2020;58(2):225–31. Cheldieva F.A., Reshetnyak T.M., Radenska-Lopovok S.G. and others. Antiphospholipid syndrome and systemic lupus erythematosus: which disease causes organ damage? Scientific and practical rheumatology. 2020;58(2):225–31 (in Russian).

For citation:Zakiev V.D., Martynyuk T.V., Kotovskaya Yu.V. Incidence and prevalence of pulmonary arterial hypertension associated with systemic lupus erythematosus. A systematic review. Clinical analysis in general medicine. 2024; 5 (2): 48–52 (In Russ.). DOI: 10.47407/ kr2023.5.2.00387


All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

  • About
  • Editorial board
  • Ethics
  • For authors
  • Author fees
  • Peer review
  • Contacts

oa
crossref
анри


  Indexing

doaj
elibrary

Address of the Editorial Office:

127055, Moscow, s/m 37

Correspondence address:

115054, Moscow, Zhukov passage, 19, fl. 2, room XI


Managing Editor:

+7 (495) 926-29-83

id@con-med.ru